Anti-CRBN / Cereblon

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml. CRBN antibody recognizes Cereblon, a substrate receptor component of the CRL4 E3 ubiquitin ligase complex that plays a central role in targeted protein degradation. Cereblon binds to the DDB1-CUL4-ROC1 complex, recruiting specific substrates for ubiquitination and subsequent proteasomal degradation. This process regulates numerous cellular pathways, including cell cycle progression, metabolism, and neuronal function. The CRBN antibody is widely used to study protein homeostasis, drug-target interactions, and the mechanism of action of immunomodulatory drugs such as thalidomide, lenalidomide, and pomalidomide, which bind Cereblon to alter substrate specificity.Cereblon is encoded by the CRBN gene located on human chromosome 3p26.2. The protein consists of 442 amino acids and contains a conserved Lon domain-like region essential for ligand binding and substrate recognition. Within the CRL4 complex, Cereblon acts as a molecular adapter, recruiting neo-substrates such as Ikaros (IKZF1), Aiolos (IKZF3), and CK1alpha in response to drug binding. This interaction forms the basis for therapeutic degradation of disease-associated transcription factors in multiple myeloma and other cancers. Loss-of-function mutations in CRBN have been linked to autosomal recessive intellectual disability, highlighting its importance in neuronal signaling and synaptic plasticity.The CRBN antibody enables detailed examination of the protein's expression and regulation across tissues. Western blot analysis typically reveals bands near 51 kDa corresponding to full-length Cereblon, while smaller isoforms may be detected in certain tissues. Immunofluorescence shows localization to both the cytoplasm and nucleus, depending on cell type and activation state. Researchers use this antibody to assess CRBN abundance in studies of proteolysis-targeting chimeras (PROTACs), a rapidly growing class of therapeutic agents that harness Cereblon for selective degradation of target proteins.Beyond oncology, CRBN influences neuronal excitability, metabolic regulation, and circadian rhythm. It has been shown to modulate BK channel activity and AMP-activated protein kinase signaling, linking it to ion channel control and energy metabolism. NSJ Bioreagents offers a validated CRBN antibody optimized for western blot, immunofluorescence, and immunoprecipitation, providing a high-quality tool for research into E3 ligase biology and drug-induced protein degradation mechanisms.